Information  X 
Enter a valid email address

Synairgen in disucssions with potential licensing partners

By BFN News | 07:57 AM | Wednesday 05 December, 2012


Synairgen announced its interim results for the six months ended 30 June 2012. Since the interim period-end, the Company has made significant progress and has progressed discussions with potential licensing partners for SNG001 (inhaled interferon beta) for asthma and COPD. These discussions are ongoing with a number of potential partners. a The company also strengthened its balance sheet with a £2.5 million (gross) fundraising in July. Richard Marsden, Chief Executive, commented on recent developments: "This has been an extremely busy period for the Company. We have significantly progressed discussions with various potential licensing partners for SNG001 in asthma and COPD and commenced biomarker and further analysis of the samples from the Phase II asthma study. "In addition, the patent portfolio has been substantially enhanced. We are excited by the potential of our lead programmes and looking forward to progressing their development in 2013." Story provided by StockMarketWire.com

a d v e r t i s e m e n t